

Breakthrough SARS-CoV-2 infections

1 Risk of hospitalization and mortality after breakthrough SARS-
2 CoV-2 infection by vaccine type and previous SARS-CoV-2
3 infection utilizing medical claims data
4

5 Meghana Kshirsagar¹, Sumit Mukherjee, Md Nasir, Nicholas Becker, Juan Lavista Ferres

6 AI for Good Research Lab, Microsoft Corporation, Redmond, WA 98052, USA

7
8 Barbra A. Richardson

9 Departments of Biostatistics and Global Health, Univ. of Washington, Seattle, WA 98195, USA

10 Vaccine and Infectious Disease Division, Fred Hutch Cancer Research Center, Seattle, WA

11 98109, USA
12

13 Word count: 1600 words

14
15 **Abstract**

16 We compare the risks of hospitalization (n=1121) and mortality (n=138) in a cohort of 17,881
17 breakthrough SARS-CoV-2 infections for the Pfizer, Moderna and Janssen vaccines for those
18 with and without SARS-CoV-2 infections prior to vaccination. Cox regression analysis results in a
19 lower hazard ratio for those receiving the Moderna vaccine, but a significantly higher hazard

¹ Corresponding author: Meghana Kshirsagar (Meghana.Kshirsagar@microsoft.com).

Address: 1 Microsoft Way, Redmond, WA 98052, phone: +1 (425) 421-8258, fax: +1 425-706-7329

The authors do not have an association that might pose a conflict of interest

No funding source

Breakthrough SARS-CoV-2 infections

20 ratio for those receiving the Janssen vaccine, as compared to those who got the Pfizer vaccine.

21 Importantly, the risk of hospitalization ($P < 0.001$) and death ($P < 0.05$) were lower among

22 individuals who had a SARS-CoV-2 infection prior to vaccination, independent of age, sex,

23 comorbidities, and vaccine type.

24

25 Keywords: breakthroughs, vaccines, Pfizer, Moderna, Janssen, SARS-CoV-2, COVID-19

26

27 **Background**

28 The combination of widespread COVID-19 vaccination and high community levels of
29 SARS-CoV-2 circulating throughout the United States has led to many breakthrough SARS-CoV-2
30 infections [1,4,5]. Breakthrough infections are generally less severe than infections in
31 unvaccinated individuals [6,7], however, severe COVID-19 disease leading to hospitalization
32 and/or death does occur among individuals who are fully vaccinated [2]. While the risk of
33 breakthrough SARS-CoV-2 infection and COVID-19 mortality have recently been reported by
34 type of vaccine [8], little to no information exists regarding risk of hospitalization by vaccine
35 type for breakthrough infections [1]. In addition, while prior SARS-CoV-2 infection is associated
36 with a lower risk of breakthrough infection, it is unknown how large an effect a prior infection
37 has on the severity of breakthrough COVID-19 infections [3].

38 COVID-19 vaccinations began in the United States in late December 2020. By late
39 February 2021, the Pfizer-BioNTech (Pfizer), Moderna, and Johnson & Johnson / J&J (Janssen)
40 vaccines were all approved for emergency use authorization (EUA). We used de-identified

Breakthrough SARS-CoV-2 infections

41 United States medical claims records from Change Healthcare to estimate the risk of
42 hospitalization and of death, by vaccine type and by previous SARS-CoV2 infection, among
43 SARS-CoV-2 breakthrough infections in those individuals fully vaccinated between Mar 10th,
44 2021 and April 27th, 2021.

45 **Methods**

46 **Ethics approval and consent to participate**

47 This study does not constitute as human subjects research due to the usage and reporting of
48 only deidentified observational data as determined by the ethics committee of the University of
49 Washington School of Medicine. An ethics approval waiver and a consent waiver were received
50 from the ethics committee of the University of Washington School of Medicine.

51

52 **Study population**

53 Our study uses claims records from Change Healthcare collected over a period from March 1,
54 2020, to Sept 30, 2021, encompassing over 100 million records from over 8 million patients.
55 This dataset includes all COVID-19 positive patients, identified by the ICD-10 diagnosis codes of
56 U07.1 (COVID-19, virus identified, lab confirmed) as the principal diagnosis. From this cohort of
57 8.18 million patients, fully vaccinated individuals are identified by looking for procedure codes
58 encoding the second doses of Pfizer (0002A) and Moderna (0012A), and the first dose of
59 Janssen (0031A). Amongst these individuals, breakthrough patients were defined as those who
60 had a COVID-19 diagnosis at least 14 days after the date of vaccination (See Supplementary
61 Figure 1 for the criteria used for cohort selection). The Pfizer and Moderna vaccination drives

Breakthrough SARS-CoV-2 infections

62 started much earlier, in late December (Supplementary Figures 2 and 3), as compared to that of
63 the Janssen vaccines, which also saw a stall in vaccine rates in mid-April (Supplementary Figure
64 4). Based on these observations, our cohort consisted of individuals who were fully vaccinated
65 between Mar 10th, 2021 – Apr 27th, 2021, the period during which all three vaccines were being
66 widely administered. These were followed from the date of vaccination up to Oct 14th, 2021.

67

68 **Statistical methods**

69 Date of full vaccination was defined as 14 days after: 1) a single Janssen vaccine; 2) the second
70 Moderna vaccine dose; or 3) the second Pfizer vaccine dose. Cox proportional hazards
71 regression was used to estimate univariate hazard ratios (HRs) and multivariable HRs in a model
72 including age (categorized), sex, vaccine type, Elixhauser comorbidities (encoded as
73 independent binary variables), and previous SARS-CoV-2 infection. Interactions between
74 vaccine type and all other covariates and previous infection and all other covariates were tested
75 but none were statistically significant. All analyses were performed using the ‘coxph’ function
76 from the R package ‘survival’ [11].

77

78

79 **Results**

80 Our study includes 17,881 fully vaccinated patients with breakthrough SARS-CoV-2 infections
81 between March 10th and Oct 14th, 2021. Of those patients, 10,011 received Pfizer, 5,028
82 received Moderna, and 2,842 received Janssen. Breakthrough cases receiving Janssen were
83 younger than those receiving Pfizer or Moderna and were slightly more likely to be male (Table

Breakthrough SARS-CoV-2 infections

84 1). Breakthrough cases receiving Moderna were more likely to have had COVID-19 prior to
85 vaccination.

86
87 Risk of hospitalization and mortality among breakthrough cases increased with older age and
88 was higher for male patients (Table 2). In multivariable analyses controlling for age, male sex,
89 comorbidities, and prior SARS-CoV-2 infection, the risk of hospitalization was lower for
90 breakthrough cases receiving the Moderna vaccine (adjusted Hazard Ratio (aHR): 0.85, 95%
91 Confidence Interval (CI) 0.74--0.99, $p < 0.05$) but was significantly higher for recipients of the
92 Janssen vaccine compared to Pfizer (aHR: 1.78, 95% CI 1.51--2.09, $p < 0.001$). There was an
93 increase in the rate of hospitalization starting ~110-125 days after full vaccination for all three
94 vaccines depending on age group, with a steeper increase for Janssen (Supplementary Figure 5
95 and 6). The comorbidities with statistically significant hazard ratios for breakthrough SARS-CoV-
96 2 infection include lung disease, cancers, hypertension, coagulopathy, renal failures, alcohol
97 abuse, anemia, seizures, and arthritis (Supplementary Table 1).

98
99 Risk of mortality for breakthrough cases receiving Pfizer and Moderna vaccines was similar, but
100 higher for Janssen recipients compared to Pfizer (aHR: 1.70, 95% CI 1.03--2.80, $p < 0.05$). Finally,
101 breakthrough cases who had a previous SARS-CoV-2 infection were half as likely to be
102 hospitalized (aHR: 0.49, 95% CI 0.35--0.69, $p < 0.001$) and four times less likely to die (aHR: 0.24,
103 95% CI 0.06--0.98, $p < 0.05$), when compared to those without a prior SARS-CoV-2 infection
104 independent of age, sex, comorbidities, and vaccine type.

105

Breakthrough SARS-CoV-2 infections

106 The time to hospitalization in breakthrough cases shows a steady increase over the 7 months
107 assessed (Supplementary Figure 7). While the number of hospitalizations increased
108 exponentially in the Delta predominance period between June 2021 and Aug 2021
109 (Supplementary Figure 8), the time to hospitalization seemed to increase by ~30 days per
110 month after the initial months of March – May when most vaccinations took place.

111

112 Discussion

113 Using medical claims data, we found that the risk of hospitalization in SARS-CoV-2 breakthrough
114 infections was lower for those receiving the Moderna vaccines, but significantly higher in those
115 receiving the Janssen vaccine, compared to Pfizer vaccine. The risk of mortality was similar in
116 breakthrough infections who received Pfizer and Moderna vaccines, but higher for those
117 receiving Janssen vaccine, compared to Pfizer vaccine. These findings are similar to those
118 reported by the CDC for mortality but provide additional information regarding risk of
119 hospitalization by vaccine type [1,2]. We also found older age, male sex, and certain
120 comorbidities to be risk factors for more severe breakthrough infections, which is similar to
121 what has been reported in prior studies of SARS-CoV-2 infections among unvaccinated
122 individuals [9].

123 Importantly, we found that risk of hospitalization was 50% less, and risk of death was 75% less,
124 in SARS-CoV-2 breakthrough infections among individuals who had a SARS-CoV-2 infection prior
125 to vaccination than for those without a previous infection. While other studies have reported
126 lower risk of breakthrough infection with previous SARS-CoV-2 infection, our study shows that

Breakthrough SARS-CoV-2 infections

127 immunity provided by previous infection seems to provide additional protection against severe
128 COVID-19 independent of vaccine type, age, comorbidities, and sex [3].

129 An important strength of our study is that we consider US-wide breakthrough hospitalizations
130 covering a broad demographic, and compare all three vaccines, whereas most previous studies
131 lack specific data on Janssen. Limitations of our study include, first, a lack of access to data on
132 unvaccinated individuals or those that had a negative SARS-CoV-2 test result. Second, the
133 medical claims data that our cohort comes from, consists of mostly privately insured individuals
134 and is thus likely to miss people with the most adverse outcomes.

135 Our findings add to the growing literature regarding SARS-CoV-2 breakthrough infections and
136 protection provided by previous SARS-CoV-2 infections against severe disease. This study
137 reinforces the need for booster vaccination shots to protect against more severe COVID-19
138 among those initially receiving the Janssen vaccine and provides new information regarding the
139 role of prior SARS-CoV-2 infection and lower risk of more severe breakthrough infections.

140

141 **References**

- 142 1. <https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status>
- 143 2. <https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalizations-vaccination>
- 144 3. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of Prior SARS-CoV-2 Infection With
145 Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. *JAMA*. Published online
146 November 01, 2021. doi:10.1001/jama.2021.19623

Breakthrough SARS-CoV-2 infections

- 147 4. Uschner, D., Bott, M., Santacatterina, M., Gunaratne, M. P., Fette, L., Burke, B. K., ... & Runyon,
148 M. (2021). Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina. medRxiv.
- 149 5. Musser, J. M., Christensen, P. A., Olsen, R. J., Long, S. W., Subedi, S., Davis, J. J., ... & Gollihar, J.
150 D. (2021). Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough
151 COVID-19 cases in Houston, Texas. medRxiv.
- 152 6. Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Tang, P., Coyle, P., Hasan, M. R., ... & Bertollini,
153 R. (2021). Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough
154 infections and reinfections. medRxiv.
- 155 7. Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., ... & Regev-Yochay, G.
156 (2021). Covid-19 breakthrough infections in vaccinated health care workers. *New England*
157 *Journal of Medicine*, 385(16), 1474-1484.
- 158 8. Liu, C., Lee, J., Ta, C., Soroush, A., Rogers, J. R., Kim, J. H., ... & Weng, C. (2021). A Retrospective
159 Analysis of COVID-19 mRNA Vaccine Breakthrough Infections-Risk Factors and Vaccine
160 Effectiveness. *medRxiv*.
- 161 9. Jin, J. M., Bai, P., He, W., Wu, F., Liu, X. F., Han, D. M., ... & Yang, J. K. (2020). Gender differences
162 in patients with COVID-19: focus on severity and mortality. *Frontiers in public health*, 8, 152.
- 163 10. Cohn, B. A., Cirillo, P. M., Murphy, C. I., Krigbaum, N. Y., Wallace, A. W. (2021). SARS-CoV-2
164 vaccine protection and deaths among US veterans during 2021. *Science*. Published online
165 November 4, 2021. doi:10.1126/science.abm0620.
- 166 11. Therneau, T., & Lumley, T. (2013). R survival package.

167

168

169

Breakthrough SARS-CoV-2 infections

170 Table 1. Characteristics of SARS-CoV-2 Breakthrough Infections Cohort tracked from March 10, 2021 to
 171 Oct 14th, 2021

Variable	Pfizer n=10,011	Moderna n=5,028	Janssen n=2,842	Overall n=17,881
Age				
0-20	98 (1.0%)	37 (0.7%)	42 (1.5%)	177 (1.0%)
20-35	947 (9.4%)	462 (9.2%)	349 (12.3%)	1,758 (9.8%)
35-50	1,647 (16.4%)	777 (15.5%)	712 (25.1%)	3,136 (17.5%)
50-64	3,269 (32.6%)	1,483 (29.5%)	1,148 (40.4%)	5,900 (33.0%)
64-80	3,391 (33.9%)	1,826 (36.3%)	500 (17.6%)	5,717 (32.0%)
>80	659 (6.6%)	443 (8.8%)	91 (3.2%)	1,193 (6.7%)
Male	4,462 (44.5%)	2,182 (43.4%)	1,322 (46.5%)	7,966 (44.6%)
Prior SARS-CoV-2 Infection	1,222 (12.2%)	1,078 (21.4%)	349 (12.3%)	2,649 (14.8%)

172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182

Table 2. Correlates of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection, estimated from Cox proportional hazards models. Hazards ratios of comorbidities are shown in Supplementary Table 1.

Variable	Hospitalization Incidence Per 100 Person Years (n/pys)	Hospitalization Univariate HR (95% CI) n=17,881	Hospitalization Multivariate aHR (95% CI) n=17,881	Mortality Incidence Per 100 Person Years (n/pys)	Mortality Univariate HR (95% CI) n=17,881	Mortality Multivariate aHR (95% CI) n=17,881
Vaccine						
<u>Pfizer</u>	20.1	1.0	1.0	2.6	1.0	1.0
Moderna	19.2	0.93 (0.8--1.1)	0.85 (0.74--0.99)*	2.3	0.89 (0.61--1.3)	0.98 (0.6--1.5)
Janssen	26.5	1.69 (1.5--2.0)***	1.78 (1.51--2.09)***	3.0	1.47 (0.98--2.2)	1.70 (1.0--2.8)*
Age						
0-20	1.9	0.29 (0.04--2.1)	0.34 (0.05--2.43)	1.9	7.48 (0.8--71.9)	8.59 (0.9--83.4)
20-35	1.9	0.27 (0.15--0.5)***	0.30 (0.16--0.56)***	0.0	0.0 (-)	0.0 (-)
<u>35-50</u>	6.8	1.0	1.0	0.3	1.0	1.0
50-64	16.9	2.08 (1.6--2.7)***	1.94 (1.51--2.49)***	1.8	5.82 (1.8--18.9)**	4.77 (1.4--15.8)*
64-80	31.7	2.96 (2.3--3.7)***	2.81 (2.20--3.59)***	3.9	12.30 (3.9-38.9)***	9.06 (2.8-29.4)***
>80	52.9	4.35 (3.3--5.7)***	3.93 (2.97--5.20)***	9.1	24.60 (7.6-79.7)***	17.10 (5.0-58.2)***
Sex						
<u>Female</u>	17.5	1.0	1.0	2.2	1.0	1.0
Male	25.0	1.38 (1.2--1.5)***	1.23 (1.09--1.39)***	3.0	1.26 (0.9-1.7)	1.10 (0.8--1.6)
Prior SARS-CoV2 Infection						
<u>No</u>	21.9	1.0	1.0	2.7	1.0	1.0
Yes	7.5	0.56 (0.4--0.8)***	0.49 (0.35--0.69)***	0.5	0.21 (0.05-0.84)*	0.24 (0.06--0.98)*

*P<0.05

**P<0.01

***P<0.001